Csl Limited (ASX:CSL)

$291.85

right-arrow Created with Sketch. -5.82 (-1.96%)
MCAP $135.6B
Last trade 12.08pm 06/12/2021 20mins delayed

Latest Announcements

09.04am 06/12/2021CSLCsl Limited
03/12/2021CSLCsl Limited
22/11/2021CSLCsl Limited
18/11/2021CSLCsl Limited
12/11/2021CSLCsl Limited
11/11/2021CSLCsl Limited
10/11/2021CSLCsl Limited
04/11/2021CSLCsl Limited

Company Overview

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.

CSL in the news

Australian drug manufacturing giant CSL (CSL) has ended FY21 with a US$2.37…
Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement…
Biotechnology company CSL (CSL) has reported a net profit after tax of…
Hopes of an Australian-made COVID-19 vaccine have been sunk after CSL and…

Search Previous Announcements